Page 83 - Read Online

Page 259 Nickoloff et al. Cancer Drug Resist 2021;4:244-63 I http://dx.doi.org/10.20517/cdr.2020.89

of irradiation with a clinical carbon SOBP beam on DNA repair deficient CHO cells. Oncol Lett 2017;13:4911-6.
94. Buglewicz DJ, Banks AB, Hirakawa H, Fujimori A, Kato TA. Monoenergetic 290 MeV/n carbon-ion beam biological lethal dose
distribution surrounding the Bragg peak. Sci Rep 2019;9:6157.
95. Kato TA, Wilson PF, Nagasaw H, et al. Variations in radiosensitivity among individuals: a potential impact on risk assessment? Health
Phys 2009;97:470-80.
96. Wilson PF, Nagasawa H, Fitzek MM, Little JB, Bedford JS. G2-phase chromosomal radiosensitivity of primary fibroblasts from
hereditary retinoblastoma family members and some apparently normal controls. Radiat Res 2010;173:62-70.
97. Kirsch DG. Current opportunities and future vision of precision medicine in radiation oncology. Int J Radiat Oncol Biol Phys
2018;101:267-70.
98. Speers C, Zhao S, Liu M, et al. Development and validation of a novel radiosensitivity signature in human breast cancer. Clin Cancer Res
2015;21:3667-77.
99. Willers H, Azzoli CG, Santivasi WL, Xia F. Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer.
Cancer J 2013;19:200-7.
100. Hill RP, Bristow RG, Fyles A, et al. Hypoxia and predicting radiation response. Semin Radiat Oncol 2015;25:260-72.
101. Kim BM, Hong Y, Lee S, et al. Therapeutic implications for overcoming radiation resistance in cancer therapy. Int J Mol Sci
2015;16:26880-913.
102. Hu J, Li H, Luo X, et al. The role of oxidative stress in EBV lytic reactivation, radioresistance and the potential preventive and therapeutic
implications. Int J Cancer 2017;141:1722-9.
103. Wardman P. Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths and mistakes. Br J Radiol
2019;92:20170915.
104. Bonnet M, Hong CR, Wong WW, et al. Next-generation hypoxic cell radiosensitizers: nitroimidazole alkylsulfonamides. J Med Chem
2018;61:1241-54.
105. Olivares-Urbano MA, Grinan-Lison C, Marchal JA, Nunez MI. CSC radioresistance: a therapeutic challenge to improve radiotherapy
effectiveness in cancer. Cells 2020;9:1651.
106. Liu Y, Yang M, Luo J, Zhou H. Radiotherapy targeting cancer stem cells “awakens” them to induce tumour relapse and metastasis in oral
cancer. Int J Oral Sci 2020;12:19.
107. Schulz A, Meyer F, Dubrovska A, Borgmann K. Cancer stem cells and radioresistance: DNA repair and beyond. Cancers 2019;11:862.
108. Talukdar S, Bhoopathi P, Emdad L, et al. Dormancy and cancer stem cells: An enigma for cancer therapeutic targeting. Adv Cancer Res
2019;141:43-84.
109. Peeken JC, Vaupel P, Combs SE. Integrating hyperthermia into modern radiation oncology: What evidence Is necessary? Front Oncol
2017;7:132.
110. Oei AL, Vriend LE, Crezee J, Franken NA, Krawczyk PM. Effects of hyperthermia on DNA repair pathways: one treatment to inhibit
them all. Radiat Oncol 2015;10:165.
111. Genet SC, Fujii Y, Maeda J, et al. Hyperthermia inhibits homologous recombination repair and sensitizes cells to ionizing radiation in a
time- and temperature-dependent manner. J Cell Physiol 2013;228:1473-81.
112. Zhu L, Altman MB, Laszlo A, et al. Ultrasound hyperthermia technology for radiosensitization. Ultrasound Med Biol 2019;45:1025-43.
113. Lewis JE, Singh N, Holmila RJ, et al. Targeting NAD Metabolism to Enhance Radiation Therapy Responses. Semin Radiat Oncol
+
2019;29:6-15.
114. Ashcraft KA, Warner AB, Jones LW, Dewhirst MW. Exercise as adjunct therapy in cancer. Semin Radiat Oncol 2019;29:16-24.
115. Schoenfeld JD, Alexander MS, Waldron TJ, et al. Pharmacological ascorbate as a means of sensitizing cancer cells to radio-chemotherapy
while protecting normal tissue. Semin Radiat Oncol 2019;29:25-32.
116. Floberg JM, Schwarz JK. Manipulation of glucose and hydroperoxide metabolism to improve radiation response. Semin Radiat Oncol
2019;29:33-41.
117. Aykin-Burns N, Pathak R, Boerma M, Kim T, Hauer-Jensen M. Utilization of vitamin E analogs to protect normal tissues while enhancing
antitumor effects. Semin Radiat Oncol 2019;29:55-61.
118. Hillman GG. Soy isoflavones protect normal tissues while enhancing radiation responses. Semin Radiat Oncol 2019;29:62-71.
119. Boss MK, Deegan R, Batinic-Haberle I, et al. Manganese porphyrin and radiotherapy improves local tumor response and overall survival
in orthotopic murine mammary carcinoma models. Radiat Res 2020; (in press).
120. Mortezaee K, Shabeeb D, Musa AE, Najafi M, Farhood B. Metformin as a radiation modifier; implications to normal tissue protection
and tumor sensitization. Curr Clin Pharmacol 2019;14:41-53.
121. Lin A, Maity A. Molecular pathways: A novel approach to targeting hypoxia and improving radiotherapy efficacy via reduction in oxygen
demand. Clin Cancer Res 2015;21:1995-2000.
122. Fernandes JM, Jandrey EHF, Koyama FC, et al. Metformin as an alternative radiosensitizing agent to 5FU during neoadjuvant treatment
for rectal cancer. Dis Colon Rectum 2020;63:918-26.
123. Farhood B, Goradel NH, Mortezaee K, et al. Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization. Clin
Transl Oncol 2019;21:268-79.
124. Citrin DE. Radiation modifiers. Hematol Oncol Clin North Am 2019;33:1041-55.
125. Livingston K, Schlaak RA, Puckett LL, Bergom C. The role of mitochondrial dysfunction in radiation-induced heart disease: from bench
to bedside. Front Cardiovasc Med 2020;7:20.
126. Thermozier S, Hou W, Zhang X, et al. Anti-ferroptosis drug enhances total-body irradiation mitigation by drugs that block apoptosis and